$0.713200
0.046.13%
Last update: 8:10 AM
15 minutes delayed
Comments
Loading...
Aptose Biosciences
APTONASDAQ
want to know what
the Bulls & Bears Say?
Aptose Biosciences (NASDAQ:APTO) Stock, Analyst Ratings, Price Targets, Forecasts
Aptose Biosciences Inc has a consensus price target of $13.86 based on the ratings of 7 analysts. The high is $38 issued by Cantor Fitzgerald on September 7, 2023. The low is $5 issued by Piper Sandler on April 3, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Canaccord Genuity, and Piper Sandler on June 14, 2024, May 16, 2024, and April 3, 2024, respectively. With an average price target of $6 between HC Wainwright & Co., Canaccord Genuity, and Piper Sandler, there's an implied 741.28% upside for Aptose Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Canaccord Genuity
Piper Sandler
RBC Capital
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for Aptose Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/14/2024 | Buy Now | 881.49% | HC Wainwright & Co. | Joseph Pantginis | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2024 | Buy Now | 741.28% | Canaccord Genuity | John Newman | $15 → $6 | Maintains | Buy | Get Alert |
| 04/03/2024 | Buy Now | 601.07% | Piper Sandler | Edward Tenthoff | $5 → $5 | Maintains | Overweight | Get Alert |
| 03/27/2024 | Buy Now | 3124.9% | HC Wainwright & Co. | Joseph Pantginis | $23 → $23 | Maintains | Buy | Get Alert |
| 02/01/2024 | Buy Now | 601.07% | Piper Sandler | Edward Tenthoff | $12 → $5 | Maintains | Overweight | Get Alert |
| 11/10/2023 | Buy Now | 2423.84% | RBC Capital | Gregory Renza | $23 → $18 | Maintains | Outperform | Get Alert |
| 09/07/2023 | Buy Now | 5228.1% | Cantor Fitzgerald | Li Watsek | → $38 | Reiterates | Overweight → Overweight | Get Alert |
| 08/11/2023 | Buy Now | 1582.56% | Piper Sandler | Edward Tenthoff | $37 → $12 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | 3124.9% | RBC Capital | Gregory Renza | $40 → $23 | Maintains | Outperform | Get Alert |
| 08/11/2023 | Buy Now | 3124.9% | HC Wainwright & Co. | Joseph Pantginis | $12 → $23 | Maintains | Buy | Get Alert |
| 08/11/2023 | Buy Now | 2003.2% | Oppenheimer | Matthew Biegler | $50 → $15 | Maintains | Outperform | Get Alert |
| 06/12/2023 | Buy Now | 3124.9% | HC Wainwright & Co. | Joseph Pantginis | $12 → $23 | Maintains | Buy | Get Alert |
| 06/12/2023 | Buy Now | 5228.1% | Cantor Fitzgerald | Li Watsek | $6 → $38 | Maintains | Overweight | Get Alert |
| 06/12/2023 | Buy Now | 6910.66% | Oppenheimer | Matthew Biegler | $9 → $50 | Maintains | Outperform | Get Alert |
| 06/07/2023 | Buy Now | 5087.89% | Piper Sandler | Edward Tenthoff | $45 → $37 | Maintains | Overweight | Get Alert |
| 06/07/2023 | Buy Now | 5508.52% | RBC Capital | Gregory Renza | $75 → $40 | Maintains | Outperform | Get Alert |
| 05/09/2023 | Buy Now | 1161.92% | Oppenheimer | Matthew Biegler | → $135 | Reiterates | → Outperform | Get Alert |
| 05/09/2023 | Buy Now | 601.07% | RBC Capital | Gregory Renza | → $75 | Reiterates | → Outperform | Get Alert |
| 05/09/2023 | Buy Now | 1582.56% | HC Wainwright & Co. | Joseph Pantginis | → $180 | Reiterates | → Buy | Get Alert |
| 03/27/2023 | Buy Now | 1021.7% | Canaccord Genuity | Carey Macrury | $195 → $120 | Maintains | Buy | Get Alert |
| 03/24/2023 | Buy Now | 601.07% | RBC Capital | Gregory Renza | → $75 | Reiterates | → Outperform | Get Alert |
| 11/02/2022 | Buy Now | 601.07% | RBC Capital | Gregory Renza | $90 → $75 | Maintains | Outperform | Get Alert |
| 05/10/2022 | Buy Now | 741.28% | RBC Capital | Gregory Renza | $105 → $90 | Maintains | Outperform | Get Alert |
| 12/21/2021 | Buy Now | 1582.56% | HC Wainwright & Co. | Joseph Pantginis | $210 → $180 | Maintains | Buy | Get Alert |
| 11/12/2021 | Buy Now | 1862.98% | HC Wainwright & Co. | Joseph Pantginis | $135 → $210 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Aptose Biosciences (APTO) stock?
The latest price target for Aptose Biosciences (NASDAQ:APTO) was reported by HC Wainwright & Co. on June 14, 2024. The analyst firm set a price target for $7.00 expecting APTO to rise to within 12 months (a possible 881.49% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aptose Biosciences (APTO)?
The latest analyst rating for Aptose Biosciences (NASDAQ:APTO) was provided by HC Wainwright & Co., and Aptose Biosciences reiterated their buy rating.
When was the last upgrade for Aptose Biosciences (APTO)?
There is no last upgrade for Aptose Biosciences
When was the last downgrade for Aptose Biosciences (APTO)?
There is no last downgrade for Aptose Biosciences.
When is the next analyst rating going to be posted or updated for Aptose Biosciences (APTO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aptose Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aptose Biosciences was filed on June 14, 2024 so you should expect the next rating to be made available sometime around June 14, 2025.
Is the Analyst Rating Aptose Biosciences (APTO) correct?
While ratings are subjective and will change, the latest Aptose Biosciences (APTO) rating was a reiterated with a price target of $7.00 to $7.00. The current price Aptose Biosciences (APTO) is trading at is $0.71, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.